- Home
- RF vs ILMN Comparison
RF vs ILMN Comparison
Compare RF & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RF | ILMN |
|---|---|---|
| Founded | 1970 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3B | 37.0B |
| IPO Year | 2007 | 2000 |
Fundamental Metrics
Financial Performance| Metric | RF | ILMN |
|---|---|---|
| Price | $26.90 | $268.09 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 22 | 21 |
| Target Price | $32.71 | ★ $202.65 |
| AVG Volume (30 Days) | ★ 7.3M | 2.3M |
| Earning Date | 10-16-2026 | 10-29-2026 |
| Dividend Yield | ★ 4.46% | N/A |
| EPS Growth | 19.17 | ★ 170.87 |
| EPS | 1.26 | ★ 2.22 |
| Revenue | $104,000,000.00 | ★ $4,343,000,000.00 |
| Revenue This Year | $3.50 | $6.47 |
| Revenue Next Year | $4.82 | $6.40 |
| P/E Ratio | ★ $21.38 | $123.85 |
| Revenue Growth | ★ 23.81 | N/A |
| 52 Week Low | $22.70 | $88.00 |
| 52 Week High | $32.47 | $278.99 |
Technical Indicators
Market Signals| Indicator | RF | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 21.19 | 73.86 |
| Support Level | $26.16 | $116.43 |
| Resistance Level | $28.36 | N/A |
| Average True Range (ATR) | 0.57 | 12.31 |
| MACD | -0.18 | 3.27 |
| Stochastic Oscillator | 0.00 | 90.76 |
Price Performance
Historical ComparisonAbout RF Regions Financial Corporation
Regions Financial is one of the midsized regional banks in the US, with around $160 billion in total assets as of the end of first quarter of 2026. Headquartered in Birmingham, Alabama, Regions Financial has a footprint mostly in the US Southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and treasury management, wealth management, and capital markets.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.